Key result
DM-MAFLD is linked to ~850% greater risk of advanced liver fibrosis versus no MAFLD.
Why the study?
The study investigated whether the fibrotic burden in the liver differs across subtypes of metabolic dysfunction-associated fatty liver disease.
Does the fibrotic burden in the liver differ across MAFLD subtypes compared to patients with no MAFLD?
Cross-Sectional (n=42,651)
Yes
Does the fibrotic burden in the liver differ across MAFLD subtypes compared to patients with no MAFLD?
Odds Ratio: 9.52 (95% CI 4.46–20.36)
Absolute Event Rate: 6.6% vs 0.2%
p-value: p=<0.001
The fibrotic burden in the liver is significantly higher in patients with DM-MAFLD compared to other MAFLD subtypes and those without MAFLD, suggesting the need for subtype-specific surveillance strategies.
No takes yet. Share an insight, caveat, or question.
DM-MAFLD subtype linked to highest fibrosis risk; supports hypothesis-generating subtype stratification but requires longitudinal validation before practice change.
Lim et al. (2023) conducted a cross-sectional in Metabolic dysfunction-associated fatty liver disease (MAFLD) (n=42,651). Diabetes mellitus MAFLD subtype (DM-MAFLD) vs. No MAFLD was evaluated on NFS-defined advanced liver fibrosis (OR 9.52, 95% CI 4.46 to 20.36, p=<0.001). Patients with the diabetes mellitus subtype of metabolic dysfunction-associated fatty liver disease had the highest risk of advanced liver fibrosis (OR 9.52) compared to those without MAFLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: